explore -WSS

explore

author：entertainment 2025-09-28 00:49:12 - browse：3

When is a billion-dollar deal a bad omen? Has Wall Street gone overboard on Ozempic? And how do you edit a chicken?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss Bristol Myers Squibb’s multibillion-dollar acquisition of Mirati Therapeutics and what it means for a biotech sector still in a slump. We also explain the latest news in the life sciences, including Wall Street’s freakout over GLP-1, CRISPR’ing animals, and the latest in the NASH saga.

For more on what we cover, here’s the news on Mirati; here’s more on biotech venture capital; here’s the latest on Alnylam Pharmaceuticals; here’s more on NASH; here’s the story on xenotransplantation; here’s more on genome-edited chickens; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： The Readout: Gilead, Bernie Sanders, and other pharma news

focus

WSS

Lawmakers grill UnitedHealth CEO on Change cyberattack

PBM executives asked to testify by House panel

Is it ever OK for doctors to lie to their patients?

Sepsis can kill a child within hours. Here's how hospitals are fighting back

How digital tools helped lower hypertension in marginalized patients

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

explore

explore

Wikipedia

ChatGPT in medicine: STAT answers readers' burning questions

Biden report: The neurospychology of memory and aging

Hepatitis C has a cure — but many Americans still lack access to it

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

State Dept. review finds Biden bears some blame for Afghanistan failures

The creative science of coining drug names

Walensky prepares to leave CDC — and Congress — behind

PhRMA lawsuit over Medicare drug price negotiation tossed

The cancer drug shortage isn’t new — and neither are the solutions

Welsh Carson private equity firm escapes from FTC antitrust case

Wikipedia

The dental labor crisis is a moment of opportunity

Vaccine advisory panel ACIP left half staffed by HHS

PBM executives asked to testify by House panel

As billionaires fund anti

Brain MRIs reveal impact of 'toxic stress' on Black children

Doctors' information doesn't help them choose wisely when sick

focus

hotspot

focus

hotspot